Advances of treatment for angioimmunoblastic T-cell lymphoma

VernacularTitle:血管免疫母细胞性T细胞淋巴瘤治疗进展
Author: Zhiyuan ZHOU ; Mingzhi ZHANG
Publication Type:Journal Article
Keywords: Immunoblastic lymphadenopathy; Lymphoma,T-cell; Hematopietic stem cell transplantation; Drug therapy,combination
From: Journal of Leukemia & Lymphoma 2013;22(9):517-519
CountryChina
Language:Chinese
Abstract: Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma (PTCL) with aggressive behaviour and poor prognosis.Due to the rarity of the disease,few prospective controlled randomized clinical trials were conducted,and the standard therapeutic option for AITL has not been established.Although conventional anthracycline-based chemotherapy achieves response rates of up to 50 ％,most of the patients relapse,the median survival time and overall survival rate are unsatisfactory.Recent studies have demonstrated that hematopietic stem cell transplantation and cyclosporine show promising efficacy in the treatment of AITL.This current review mainly focused on the advance of treatment for AITL.